TY - JOUR
T1 - A decade of cell death studies
T2 - Breathing new life into necroptosis
AU - Khan, Imran
AU - Yousif, Abdelrahman
AU - Chesnokov, Mikhail
AU - Hong, Linda
AU - Chefetz, IIana I.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.
AB - Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.
KW - Cancer
KW - Cardiovascular disorders
KW - Cell death
KW - Cell programmed necrosis
KW - MLKL
KW - Necroptosis
KW - Neurodegenerative diseases
KW - RIPK1
KW - RIPK3
UR - http://www.scopus.com/inward/record.url?scp=85095810425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095810425&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2020.107717
DO - 10.1016/j.pharmthera.2020.107717
M3 - Article
C2 - 33164841
AN - SCOPUS:85095810425
SN - 0163-7258
VL - 220
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
M1 - 107717
ER -